Pfizer's Lyme Disease Vaccine Shows 70% Efficacy

Twenty-four years after the only Lyme disease vaccine was pulled from the U.S. market under pressure from lawsuits and advocacy campaigns, Pfizer and its partner Valneva announced on March 23, 2026, that their candidate vaccine demonstrated more than 70% efficacy in preventing Lyme disease [1][2]. The announcement marks a significant milestone in the long effort to develop a second-generation Lyme vaccine—but a failure to meet the trial's primary statistical threshold has complicated the picture, sending Valneva's stock price down more than 35% and raising questions about the regulatory road ahead [3].

The VALOR Trial: What the Data Shows

The Phase 3 VALOR trial enrolled approximately 9,400 healthy participants aged five years and older at clinical sites across the United States, Canada, and Europe—all in areas where Lyme disease is endemic [1][4]. Participants received four doses of PF-07307405, formerly known as VLA15, at months 0, 2, and 5–9, with a booster dose approximately one year after the third injection, timed to precede peak tick season [5].

The vaccine demonstrated efficacy of 73.2% in reducing confirmed Lyme disease cases, measured from 28 days after the fourth dose compared to placebo [1][2]. A secondary analysis showed 74.8% efficacy beginning one day after the fourth dose [4].

But the headline numbers obscure a problem. The trial's pre-specified primary endpoint required the lower bound of the 95% confidence interval to exceed 20%—a standard regulatory threshold intended to ensure the observed efficacy isn't a statistical artifact. The first analysis fell short: the lower bound came in at just 15.8% [3][4]. This miss was attributed to fewer Lyme disease cases than anticipated during the study period, which reduced the trial's statistical power.

A second pre-specified analysis fared better, with the confidence interval's lower bound reaching 21.7%—just clearing the bar [1]. Pfizer and Valneva have said these results "strengthen confidence" in the vaccine and that they intend to proceed with regulatory submissions [2].

"Lyme disease can cause potentially serious consequences—where individuals and families face symptoms that can disrupt daily life, work, and long-term health—and there is currently no vaccine available," said Annaliesa Anderson, Pfizer's Chief Vaccines Officer [1].

How 70% Efficacy Stacks Up

A 73% efficacy rate places this vaccine in the middle of the pack compared to other widely used immunizations. The MMR vaccine achieves roughly 97% efficacy against measles [6]. Annual influenza vaccines typically range between 40% and 60% effectiveness depending on the season and strain match [6]. Current COVID-19 boosters show efficacy in the range of 50–60% against symptomatic infection from circulating variants [6].

The FDA does not maintain a single fixed efficacy threshold for vaccine approval. Rather, the agency evaluates each candidate based on the disease's severity, the availability of alternatives, and the strength of the overall data package. For the Lyme vaccine specifically, the 20% lower bound for the confidence interval was the agreed-upon benchmark—a threshold the trial narrowly met in one analysis and missed in another [3][4].

Whether this split result satisfies the FDA will depend heavily on the totality of evidence Pfizer presents, including safety data, immunogenicity results, and the practical significance of preventing a disease that, while rarely fatal, can cause debilitating long-term symptoms.

The Scale of the Lyme Problem

The burden of Lyme disease in the United States has grown substantially since the first vaccine was withdrawn. The CDC estimates that approximately 476,000 people are diagnosed and treated for Lyme disease annually in the U.S., though many of these cases are treated on clinical suspicion rather than confirmed diagnosis [7]. Over 89,000 cases were formally reported to the CDC in 2023 [7]. In Europe, approximately 132,000 cases are reported each year [3].

The disease is concentrated in the northeastern United States—Connecticut, Massachusetts, New York, Pennsylvania, New Jersey—the mid-Atlantic states, and the upper Midwest, particularly Minnesota and Wisconsin [8]. But the geographic range of the blacklegged tick (Ixodes scapularis) that carries Borrelia burgdorferi has been expanding, with 2023 county-level data showing Lyme spreading beyond its traditional strongholds [8].

The economic costs are significant. CDC-funded research estimated per-patient costs at approximately $1,200 for an initial infection, with patients who progress to later stages of disease incurring roughly double that amount [9]. A separate analysis found that Lyme disease patients carry an average of $3,000 in additional annual healthcare costs, adding up to an estimated $712 million to $1.3 billion burden on the U.S. healthcare system per year [9]. About 10–20% of treated patients develop Post-Treatment Lyme Disease Syndrome (PTLDS), a condition involving persistent fatigue, pain, and cognitive difficulties that can last months or years [7].

Source: CDC Lyme Disease Surveillance Data

Data as of Mar 23, 2026CSV

The Ghost of LYMErix

Any discussion of a new Lyme vaccine inevitably circles back to LYMErix, the vaccine developed by SmithKline Beecham (later GlaxoSmithKline) that was approved by the FDA in 1998 and pulled from the market by 2002 [10][11].

LYMErix was a recombinant vaccine based on the outer surface protein A (OspA) of Borrelia burgdorferi. Clinical trials demonstrated 76% efficacy after three doses—numbers comparable to the current candidate [11][12]. Approximately 1.4 million doses were distributed in the United States [10].

The controversy centered on a 1998 study by lead researcher Dr. Allan Steere, published before the vaccine's approval, suggesting that OspA could trigger a cross-reaction with a human protein in individuals carrying the HLA-DR4 gene—a genetic variant present in 20–30% of the population [10]. This raised theoretical concerns about autoimmune arthritis.

Anti-vaccine groups seized on the finding. A Philadelphia law firm filed a class-action lawsuit in 1999 on behalf of 121 individuals claiming adverse reactions [12]. Media coverage amplified the fears. Although the Vaccine Adverse Event Reporting System (VAERS) logged only 59 reports of arthritis among the 1.4 million doses distributed—a rate no higher than the background incidence in unvaccinated individuals—public confidence collapsed [10]. The FDA conducted a thorough safety review in 2001 and found "no proof that the LYMErix vaccine was dangerous" [12].

GlaxoSmithKline withdrew LYMErix in February 2002, citing "insufficient consumer demand" [10][11]. The company settled the class-action lawsuit without providing compensation to claimants [12]. Since the CDC had not recommended LYMErix for routine vaccination, it received no protection under the National Vaccine Injury Compensation Program—leaving the manufacturer exposed to civil litigation in a way that vaccines on the childhood schedule are not [12].

How the New Vaccine Differs

The current candidate, PF-07307405, also targets OspA but with a broader approach. While LYMErix targeted a single OspA serotype from North American Borrelia burgdorferi, the new vaccine is a hexavalent formulation—it targets six OspA serotypes covering the multiple Borrelia species responsible for Lyme disease in both North America and Europe [5][13]. This broader coverage is one reason the VALOR trial was conducted across three continents.

The safety profile from the Phase 3 trial has been described as "well tolerated with no safety concerns identified at the time of analysis" [1][2]. Full safety data will be part of the regulatory submission. The trial enrolled a substantial population of roughly 9,400 participants, though this number is lower than originally planned—Pfizer and Valneva had to remove approximately half the trial participants earlier after discovering Good Clinical Practice (GCP) violations at sites run by third-party trial operator Care Access [14]. This reduction contributed to the lower-than-expected case count that undermined the trial's statistical power.

Dosing, Cost, and Practical Considerations

The four-dose primary schedule—administered at months 0, 2, and 5–9, plus a booster before the next tick season—represents a more complex regimen than many standard vaccines [5]. Phase 2 data also support annual boosters to maintain antibody levels through subsequent Lyme seasons [13].

Pfizer has not disclosed pricing for the vaccine. For context, current Lyme prevention measures carry their own costs: permethrin-treated clothing runs $50–100 per season, and prophylactic doxycycline prescribed after known tick bites costs relatively little per course but requires timely recognition of the bite [7]. Landscape management techniques such as deer exclusion fencing and targeted acaricide applications can cost hundreds to thousands of dollars annually for homeowners in endemic areas.

If the vaccine reaches market, the question of who should receive it will shape its public health impact. The Advisory Committee on Immunization Practices (ACIP) has historically recommended that Lyme vaccination decisions be made based on individual risk assessment, considering geographic location and tick exposure from occupational or recreational activities [8]. Research on vaccine acceptability has identified key target populations: parents of children aged 5–10, adults aged 45–60, and individuals previously diagnosed with Lyme disease [8].

For the vaccine to meaningfully reduce Lyme disease incidence in endemic areas, vaccination rates would need to be substantial—a challenge given the four-dose regimen and the fact that Lyme, while debilitating, is rarely life-threatening. The disease's concentration in specific geographic corridors may argue for a targeted vaccination strategy rather than universal recommendation.

The Regulatory Path Forward

Pfizer has announced plans to submit a Biologics License Application (BLA) to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency in 2026 [2][3]. If approved on a standard timeline, the vaccine could reach the market in the second half of 2027 [3].

But the path has already been bumpy. The regulatory filing was pushed back by a year after the Care Access GCP violations forced the removal of roughly half the trial participants [14]. The primary endpoint miss adds another layer of uncertainty. The FDA will need to weigh the totality of the evidence—the strong point estimate of 73% efficacy, the one analysis that cleared the confidence interval threshold, the safety profile, and the unmet medical need.

The political environment adds further complexity. Senator Rand Paul introduced the "End the Vaccine Carveout Act" in early 2026, which would eliminate liability protections for vaccine manufacturers under the National Childhood Vaccine Injury Act [12]. While the bill targets childhood vaccines specifically, it reflects a broader political climate of vaccine skepticism that could affect public acceptance of any new immunization. Increasing vaccine hesitancy more broadly has some advocates concerned that politics could impede new Lyme vaccines even if they clear regulatory hurdles [15].

The Advocacy Landscape

The Lyme disease patient community is not monolithic on the vaccine question. Over 500 Lyme and tick-borne disease advocates participated in an Advocacy Day in February 2026, meeting with 351 congressional offices across all 50 states [16]. Their agenda focused on research funding and access to care, but the vaccine remained a live topic.

Some of the same advocacy organizations that opposed LYMErix have expressed skepticism about the new candidate. LymeDisease.org has described the vaccine's history as "complex," raising questions about the OspA mechanism that echo concerns from the early 2000s [17]. Other groups, including the American Lyme Disease Foundation, have been more supportive, emphasizing the need for prevention tools given the disease's expanding geographic range [11].

The scientific consensus is clear: no causal link between OspA-based vaccines and autoimmune disease was ever established [10][11]. The FDA's 2001 review, independent academic analyses, and VAERS data all pointed to the same conclusion. But consensus does not automatically translate into public trust, particularly when the memory of LYMErix's withdrawal remains vivid for many in the Lyme community.

For Pfizer, the challenge extends beyond regulatory approval. Even with an FDA green light, the company will need to convince clinicians, insurers, and patients that this vaccine is worth a four-dose commitment. The 73% efficacy figure, while meaningful, is not the kind of number that drives enthusiastic uptake on its own. The vaccine's success or failure may ultimately depend less on the science and more on whether Pfizer can avoid the communication failures and advocacy opposition that sank its predecessor.

Source: CDC, Pfizer, published clinical trial data

Data as of Mar 23, 2026CSV

What Comes Next

The coming months will determine whether PF-07307405 becomes the first Lyme disease vaccine approved since LYMErix. The FDA's review of the BLA submission—expected in 2026—will set the pace. If the agency requires additional data or a supplementary trial to address the confidence interval shortfall, the timeline could stretch further.

Meanwhile, Lyme disease cases continue to climb. The geographic range of infected ticks is expanding due to warming temperatures and changing land use patterns. An estimated 476,000 Americans are treated for the disease each year, at a cost that runs into the billions [7][9]. Since LYMErix's withdrawal, reported cases have roughly quadrupled [12].

Whether this vaccine reaches patients will test not just the strength of the clinical data, but the resilience of a public health system still grappling with the legacy of the last attempt.